Opinion|Videos|June 5, 2024
Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations
Author(s)Neal Shore, MD
Neal Shore, MD, FACS, discusses the safety profiles reported across the nadofaragene firadenovec, SunRISe-1, and NURE-COMBO trials, highlighting any unexpected toxicities observed with these novel therapies for non-muscle-invasive and muscle-invasive bladder cancer. Additionally, he reviews key limitations of the study designs or patient populations that may impact the interpretation and generalizability of the results from these trials.
Advertisement
Video content above is prompted by the following question(s):
- Discuss the safety profiles reported across these three trials. Were there any new or unexpected toxicities observed with the novel therapies compared to standard treatments?
Advertisement
Related to this article
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
Medicaid Obesity GLP-1 Coverage May Offset Some Diabetes-Labeled Use
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5